Biocon shares gain after Health Canada approval for injection used in treating bloodstream infections
Biocon Pharma Limited, a subsidiary of Biocon, has received approval from Health Canada for its Micafungin for Injection, USP (50 mg and 100 mg). This antifungal medication is indicated for treating various fungal infections in adults and pediatric patients, and for prophylaxis in hematopoietic stem cell transplant patients. This regulatory clearance is expected to enhance Biocon's integrated biosimilars and generics portfolio and expand its presence in the Canadian market.
May 11 2026 10:05:00
Kiran Mazumdar-Shaw names niece Claire as successor, targets semaglutide push from FY28; debt cut to $1.1 billion
Biocon's Executive Chairperson, Kiran Mazumdar-Shaw, has named her niece Claire Mazumdar as her successor, outlining a five-year transition plan. The company also announced plans to target peak revenue of $500 million to $700 million from Semaglutide by FY30, with a push starting from FY28, and aims to reduce its current debt of $1.8 billion to $1.1 billion by FY28.
May 11 2026 09:05:00
Biocon Ltd - 532523 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Biocon has initiated a Postal Ballot for shareholder approval on several key resolutions. These include revisions to Executive Chairperson's remuneration, the appointment of Shreehas Pradeep Tambe as CEO & MD, and a preferential issue of equity shares to acquire the remaining minority stake in Biocon Biologics, making it a wholly-owned subsidiary for strategic integration.
May 09 2026 01:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Biocon announced the availability of the audio and video recording of its Q4 FY26 Earnings Call, held on May 08, 2026. Investors can access the recording via links provided on the company's website.
May 08 2026 21:05:00
Biocon Q4 Results: Net profit down 57% at Rs 198.6 crore
Biocon Ltd. reported a significant decline in its Q4 FY26 net profit, falling 56.8% to ₹198.6 crore, primarily due to an ₹80.4 crore exceptional item. Despite the profit drop, the company's consolidated revenue for the quarter increased to ₹4516.6 crore. For the full fiscal year 2026, net profit also decreased to ₹368.8 crore, while revenue grew to ₹16927 crore.
May 08 2026 10:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
Biocon's monitoring agency report confirms full utilization of over Rs.8,650 crore QIP funds as per stated objects for Q4 FY26. The funds were primarily used for acquisitions and debt repayment across two QIPs.
May 08 2026 00:05:00
Biocon Ltd - 532523 - Outcome Of Board Meeting_Change In Long Term Incentive Plan
Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Issue of Securities
Biocon's Board approved a preferential issue of 87.92 lakh equity shares at Rs. 376.16 per share, totaling Rs. 330.73 crore. This issuance is to acquire the remaining ~2% stake in its material subsidiary, Biocon Biologics Limited (BBL), aiming for full integration and simplified corporate structure.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Announcement under Regulation 30 (LODR)-Acquisition
Biocon plans to acquire the remaining ~2% equity stake in its material subsidiary, Biocon Biologics. The acquisition, valued at Rs. 330.73 crores through a preferential issue of Biocon shares, will increase its ownership to approximately 99.99%, aiming to fully integrate the biosimilars business.
May 07 2026 23:05:00
Biocon Ltd - 532523 - Outcome Of Board Meeting_Completion Of Tenure Of Statutory Auditors
Biocon's Board approved the acquisition of the remaining ~2% equity shares in its material subsidiary, Biocon Biologics Limited (BBL). This acquisition, valued at Rs.330.73 crores through a preferential issue of Biocon shares, aims for full integration and operational synergies, making BBL a nearly 99.99% owned subsidiary.
May 07 2026 23:05:00
Read More